9.90
9.90 (0%)
As of Feb 14, 2025
Allovir, Inc. [ALVR]
Source:
Company Overview
AlloVir, Inc is a biopharmaceutical company. AlloVir’s initial focus was on developing highly innovative allogeneic T cell therapies to treat and prevent devastating viral diseases.
| Country | United States |
| Headquarters | waltham, massachusetts |
| Phone Number | (617) 433-2605 |
| Industry | manufacturing |
| CEO | Diana Brainard |
| Website | www. |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | |
| Operating Profit | $-65.4 |
| Net Income | $-58.8 |
| Net Cash | $27.3 |
Profit Ratios
| Gross Margin | $0 |
| Operating Margin | |
| Profit as % of Revenues | |
| Profit as % of Assets | -38% |
| Profit as % of Stockholder Equity | -51.9% |
Management Effectiveness
| Return on Equity | -51.9% |
| Return on Assets | -49.6% |
| Turnover Ratio | |
| EBITA | $-65.4 |
Balance Sheet and Cash Flow Measures
| Total Assets | $118.5 |
| Total Liabilities | $5.2 |
| Operating Cash Flow | $-67.7 |
| Investing Cash Flow | $95 |
| Financing Cash Flow | $0 |
